Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557310 · ClinicalTrials.gov registry record · Phase 4
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
A Phase 4 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT00557310 is a Phase 4 study of Osteoporosis, Postmenopausal that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants, below the 3,256-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00557310, a Phase 4 study of Osteoporosis, Postmenopausal, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
Conditions Studied
Interventions
- DRUG teriparatide
Study Locations (6)
Arizona
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Tucson
Colorado
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lakewood
Nebraska
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Omaha
New Mexico
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Albuquerque
Pennsylvania
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Pittsburgh
British Columbia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557310
The ClinicalTrials.gov registry entry for NCT00557310 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,256-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 1 intervention - of which teriparatide is the first listed.
NCT00557310 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Colorado, Nebraska.
Frequently Asked Questions
What is clinical trial NCT00557310 about?
NCT00557310 is a clinical study titled "A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide". The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
What is the current status of trial NCT00557310?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2007-11. Estimated completion is 2011-05.
What conditions does trial NCT00557310 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT00557310?
The interventions under investigation include: teriparatide (DRUG).
Who is sponsoring clinical trial NCT00557310?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00557310 being conducted?
This trial has 6 study locations across Arizona, Colorado, Nebraska, New Mexico, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
-
Mechanisms of Anabolic Osteoporosis Therapy
RECRUITING · NA
-
Comparative Efficacy, Safety, PK, and Immunogenicity Study
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.